{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T14:33:20Z","timestamp":1781361200880,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urology.2025.07.016","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:22:41Z","timestamp":1752765761000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Five-Year Outcomes of Water Vapor Therapy vs Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data From the Medical Therapy of Prostatic Symptoms Trial"],"prefix":"10.1016","volume":"206","author":[{"given":"Bronwyn","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandip","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Copelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Feffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"McVary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.07.016_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5213\/inj.2040412.206","article-title":"Changes in prevalence and treatment pattern of benign prostatic hyperplasia in Korea","volume":"25","author":"Jo","year":"2021","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.urology.2025.07.016_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0302-2838(03)00376-2","article-title":"Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project","volume":"44","author":"Verhamme","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group","volume":"335","author":"Lepor","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.07.016_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.07.016_bib5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.07.016_bib6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study","volume":"68","author":"Cindolo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266824","article-title":"A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia","volume":"17","author":"Chughtai","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2025.07.016_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/JU.0000000000001778","article-title":"Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"206","author":"McVary","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jsxm.2016.03.372","article-title":"Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study","volume":"13","author":"McVary","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2025.07.016_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11934-017-0721-8","article-title":"Can long-term LUTS\/BPH pharmacological treatment alter the outcomes of surgical intervention?","volume":"18","author":"Presicce","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2025.07.016_bib11","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.07.016_bib12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.juro.2015.10.181","article-title":"Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"195","author":"McVary","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib13","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2025.07.016_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0197-2456(02)00263-5","article-title":"Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial","volume":"24","author":"Bautista","year":"2003","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.urology.2025.07.016_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.juro.2018.02.3088","article-title":"Three-year treatment outcomes of water vapor thermal therapy compared to Doxazosin, Finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS Trial","volume":"200","author":"Gupta","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib16","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib17","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.juro.2009.01.033","article-title":"Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia","volume":"181","author":"Nichol","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ijcp.12241","article-title":"Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"68","author":"Koh","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2025.07.016_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1742-1241.2007.01635.x","article-title":"Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey","volume":"62","author":"Emberton","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2025.07.016_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1742-1241.2006.01129.x","article-title":"Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey","volume":"60","author":"Kaplan","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2025.07.016_bib21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jsxm.2018.10.006","article-title":"Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?","volume":"15","author":"McVary","year":"2018","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2025.07.016_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-5347(01)63011-8","article-title":"5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study","volume":"160","author":"Flanigan","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1464-410X.2010.09737.x","article-title":"Impact of medical therapy on transurethral resection of the prostate: two decades of change","volume":"108","author":"Izard","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2025.07.016_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1464-410X.1988.tb04428.x","article-title":"Serial residual volumes in men with prostatic hypertrophy","volume":"62","author":"Birch","year":"1988","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0090-4295(82)90308-9","article-title":"Value of postvoid residual urine determination in evaluation of prostatism","volume":"20","author":"Bruskewitz","year":"1982","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.07.016_bib26","first-page":"167","article-title":"No relationship between the international prostate symptom score and post void residual volume in primary care","volume":"12","author":"Lammers","year":"2020","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urology.2025.07.016_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0090-4295(96)00206-3","article-title":"Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score","volume":"48","author":"Ezz el Din","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.07.016_bib28","first-page":"NC01","article-title":"Experience with uroflowmetry in evaluation of lower urinary tract symptoms in patients with benign prostatic hyperplasia","volume":"8","author":"Singla","year":"2014","journal-title":"J Clin Diagn Res"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525006922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525006922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:56:50Z","timestamp":1772791010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525006922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S0090429525006922"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.07.016","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-Year Outcomes of Water Vapor Therapy vs Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data From the Medical Therapy of Prostatic Symptoms Trial","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}